Inflammatory pathways in Parkinsons disease; A BNE microarray study

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Durrenberger, Pascal F ^a   Grünblatt, Edna ^b,c   Fernando, Francesca S ^a   Monoranu, Camelia Maria ^d   Evans, Jordan ^a   Riederer, Peter ^b   Reynolds, Richard ^a   Dexter, David T ^a  

^a Faculty of Medicine   (United Kingdom)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA SYNUCLEIN; DOPAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIGAND GATED ION CHANNEL; PURINERGIC P2X7 RECEPTOR;

ADULT; AGED; ARTICLE; ASTROCYTE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOPAMINE METABOLISM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; MALE; MICROARRAY ANALYSIS; MICROGLIA; NERVE CELL GROWTH; NERVE CELL NECROSIS; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATIENT SAFETY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TREATMENT PLANNING;

EID: 84861083668     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/214714     Document Type: Article

References (76)

1. de Lau L. M., Breteler M. M., Epide (Pubitemid 44262284)
2. Alves G., Forsaa E. B., Pedersen K. F., Gjerstad M. D., Larsen J. P., Epidemiology of Parkinson's disease Journal of Neurology 2008 255 supplement 5 18 32
3. O'Sullivan S. S., Williams D. R., Gallagher D. A., Massey L. A., Silveira-Moriyama L., Lees A. J., Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study Movement Disorders 2008 23 1 101 106 (Pubitemid 351281225)
4. Gelb D. J., Oliver E., Gilman S., Diagnostic criteria for Parkinson disease Archives of Neurology 1999 56 1 33 39 (Pubitemid 29046907)
5. Aarsland D., Larsen J. P., Lim N. G., Range of neuropsychiatric disturbances in patients with Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry 1999 67 4 492 496 (Pubitemid 29438205)
6. Langston J. W., The Parkinson's complex: parkinsonism is just the tip of the iceberg Annals of Neurology 2006 59 4 591 596
7. Jankovic J., Parkinson's disease: clinical features and diagnosis Journal of Neurology, Neurosurgery and Psychiatry 2008 79 4 368 376 (Pubitemid 351441488)
8. Olanow C. W., Stern M. B., Sethi K., The scientific and clinical basis for the treatment of Parkinson disease Neurology 2009 72 21, supplement 4 S1 S136
9. Sulzer D., Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease Trends in Neurosciences 2007 30 5 244 250 (Pubitemid 46667168)
10. Obeso J. A., Rodriguez-Oroz M. C., Goetz C. G., Missing pieces in the Parkinson's disease puzzle Nature Medicine 2010 16 6 653 661
11. Mandel S. A., Fishman T., Youdim M. B., Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD Parkinsonism and Related Disorders 2007 13 supplement 3 S242 S247
12. Hauser M. A., Li Y. J., Xu H., Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism Archives of Neurology 2005 62 6 917 921 (Pubitemid 40973453)
13. Zhang Y., James M., Middleton F. A., Davis R. L., Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms American Journal of Medical Genetics B 2005 137 1 5 16 (Pubitemid 41076605)
14. Moran L. B., Duke D. C., Deprez M., Dexter D. T., Pearce R. K., Graeber M. B., Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease Neurogenetics 2006 7 1 1 11 (Pubitemid 43327678)
15. Lesnick T. G., Papapetropoulos S., Mash D. C., A genomic pathway approach to a complex disease: axon guidance and Parkinson disease PLoS Genetics 2007 3 6, article e98
16. Bossers K., Meerhoff G., Balesar R., Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death Brain Pathology 2009 19 1 91 107
17. Grunblatt E., Mandel S., Jacob-Hirsch J., Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin- proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes Journal of Neural Transmission 2004 111 12 1543 1573 (Pubitemid 40068786)
18. Cantuti-CastelvetriI I., Keller-McGandy C., Bouzou B., Effects of gender on nigral gene expression and Parkinson disease Neurobiology of Disease 2007 26 3 606 614 (Pubitemid 46756328)
19. Soreq L., Israel Z., Bergman H., Soreq H., Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients Journal of Neuroimmunology 2008 201-202 227 236
20. Scherzer C. R., Eklund A. C., Morse L. J., Molecular markers of early Parkinson's disease based on gene expression in blood Proceedings of the National Academy of Sciences of the United States of America 2007 104 3 955 960 (Pubitemid 46154718)
21. Zheng B., Liao Z., Locascio J. J., PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease Science Translational Medicine 2010 2 52
22. Bell J. E., Alafuzoff I., Al-Sarraj S., Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium Acta Neuropathologica 2008 115 5 497 507
23. Schroeder A., Mueller O., Stocker S., The RIN: an RNA integrity number for assigning integrity values to RNA measurements BMC Molecular Biology 2006 7, article 3
24. Copois V., Bibeau F., Bascoul-Mollevi C., Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality Journal of Biotechnology 2007 127 4 549 559 (Pubitemid 44959110)
25. Weng L., Dai H., Zhan Y., He Y., Stepaniants S. B., Bassett D. E., Rosetta error model for gene expression analysis Bioinformatics 2006 22 9 1111 1121
26. Durrenberger P. F., Fernando S., Kashefi S. N., Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study Journal of Neuropathology and Experimental Neurology 2010 69 1 70 81
27. Sutherland G. T., Matigian N. A., Chalk A. M., A cross-study transcriptional analysis of Parkinson's disease PLoS One 2009 4 3
28. Danese S., Dejana E., Fiocchi C., Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation Journal of Immunology 2007 178 10 6017 6022 (Pubitemid 46717378)
29. Mandel S., Grunblatt E., Riederer P., Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70 Annals of the New York Academy of Sciences 2005 1053 356 375 (Pubitemid 43031116)
30. Marchitti S. A., Brocker C., Stagos D., Vasiliou V., Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily Expert Opinion on Drug Metabolism and Toxicology 2008 4 6 697 720 (Pubitemid 352003194)
31. Galter D., Buervenich S., Carmine A., Anvret M., Olson L., ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia Neurobiology of Disease 2003 14 3 637 647 (Pubitemid 37547970)
32. Marchitti S. A., Deitrich R. A., Vasiliou V., Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase Pharmacological Reviews 2007 59 2 125 150 (Pubitemid 46855437)
33. Grunblatt E., Zehetmayer S., Jacob C. P., Muller T., Jost W. H., Riederer P., Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease Journal Neural Transmission 2010 117 12 1387 1393
34. Jacobs F. M., Smits S. M., Noorlander C. W., Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency Development 2007 134 14 2673 2684 (Pubitemid 47225963)
35. Nunes I., Tovmasian L. T., Silva R. M., Burke R. E., Goff S. P., Pitx3 is required for development of substantia nigra dopaminergic neurons Proceedings of the National Academy of Sciences of the United States of America 2003 100 7 4245 4250 (Pubitemid 36418188)
36. Maxwell S. L., Ho H. Y., Kuehner E., Zhao S., Li M., Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development Developmental Biology 2005 282 2 467 479 (Pubitemid 40799336)
37. North R. A., Molecular physiology of P2X receptors Physiological Reviews 2002 82 4 1013 1067
38. Inoue K., Microglial activation by purines and pyrimidines Glia 2002 40 2 156 163 (Pubitemid 35337373)
39. Schipke C. G., Boucsein C., Ohlemeyer C., Kirchhoff F., Kettenmann H., Astrocyte Ca 2+ waves trigger responses in microglial cells in brain slices The FASEB Journal 2002 16 2 255 257
40. Di Virgilio F., Ceruti S., Bramanti P., Abbracchio M. P., Purinergic signalling in inflammation of the central nervous system Trends in Neurosciences 2009 32 2 79 87
41. Apolloni S., Montilli C., Finocchi P., Amadio S., Membrane compartments and purinergic signalling: P2X receptors in neurodegenerative and neuroinflammatory events The FEBS Journal 2009 276 2 354 364
42. Burnstock G., Purinergic regulation of vascular tone and remodelling Autonomic and Autacoid Pharmacology 2009 29 3 63 72
43. Suzuki T., Hide I., Ido K., Kohsaka S., Inoue K., Nakata Y., Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia Journal of Neuroscience 2004 24 1 1 7 (Pubitemid 38181664)
44. Ferrari D., Pizzirani C., Adinolfi E., The P2X7 receptor: a key player in IL-1 processing and release Journal of Immunology 2006 176 7 3877 3883 (Pubitemid 44264361)
45. Kataoka A., Tozaki-Saitoh H., Koga Y., Tsuda M., Inoue K., Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT Journal of Neurochemistry 2009 108 1 115 125
46. Parvathenani L. K., Tertyshnikova S., Greco C. R., Roberts S. B., Robertson B., Posmantur R., P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease The Journal of Biological Chemistry 2003 278 15 13309 13317 (Pubitemid 36800102)
47. Gendron F. P., Chalimoniuk M., Strosznajder J., P2X7 nucleotide receptor activation enhances IFN gamma-induced type II nitric oxide synthase activity in BV-2 microglial cells Journal of Neurochemistry 2003 87 2 344 352 (Pubitemid 37255242)
48. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T., Tumor necrosis factor- (TNF- ) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neuroscience Letters 1994 165 1-2 208 210
49. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T., Interleukin (IL)-1, IL-2, IL-4, IL-6 and transforming growth factor- levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease Neuroscience Letters 1996 211 1 13 16 (Pubitemid 26228016)
50. Blum-Degen D., Mller T., Kuhn W., Gerlach M., Przuntek H., Riederer P., Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Neuroscience Letters 1995 202 1-2 17 20
51. Croisier E., Moran L. B., Dexter D. T., Pearce R. K., Graeber M. B., Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition Journal of Neuroinflammation 2005 2, article 14
52. Gerhard A., Pavese N., Hotton G., In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiology of Disease 2006 21 2 404 412 (Pubitemid 43099863)
53. Chen H., Jacobs E., Schwarzschild M. A., Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease Annals of Neurology 2005 58 6 963 967 (Pubitemid 41746889)
54. McCoy M. K., Tansey M. G., TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease Journal of Neuroinflammation 2008 5, article 45
55. Zhang F., Zhou H., Wilson B. C., Shi J. S., Hong J. S., Gao H. M., Fluoxetine protects neurons against microglial activation-mediated neurotoxicity Parkinsonism and Related Disorders 2012 18 supplement 1 S213 S217
56. Coutinho-Silva R., Perfettini J. L., Persechini P. M., Dautry-Varsat A., Ojcius D. M., Modulation of P2Z/P2X(7) receptor activity in macrophages infected with Chlamydia psittaci American Journal of Physiology Cell Physiology 2001 280 1 C81 C89
57. McLarnon J. G., Ryu J. K., Walker D. G., Choi H. B., Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus Journal of Neuropathology and Experimental Neurology 2006 65 11 1090 1097 (Pubitemid 44684667)
58. Sanz J. M., Chiozzi P., Ferrari D., Activation of microglia by amyloid (beta) requires P2X7 receptor expression Journal of Immunology 2009 182 7 4378 4385
59. Lawson L. J., Perry V. H., Dri P., Gordon S., Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain Neuroscience 1990 3 1 151 170
60. Marcellino D., Suarez-Boomgaard D., Sanchez-Reina M. D., On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079 Journal of Neural Transmission 2010 117 6 681 687
61. Labasi J. M., Petrushova N., Donovan C., Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response Journal of Immunology 2002 168 12 6436 6445 (Pubitemid 34620068)
62. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A. L., Rey P., Guerra M. J., Labandeira-Garcia J. L., The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease Journal of Neurochemistry 2009 109 2 656 669
63. Saavedra J. M., Sanchez-Lemus E., Benicky J., Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications Psychoneuroendocrinology 2011 36 1 1 18
64. Muramatsu Y., Kurosaki R., Watanabe H., Cerebral alterations in a MPTP-mouse model of Parkinson's diseasean immunocytochemical study Journal Neural Transmission 2003 110 10 1129 1144 (Pubitemid 37271856)
65. Wright D. H., Abran D., Bhattacharya M., Prostanoid receptors: ontogeny and implications in vascular physiology American Journal of Physiology 2001 281 5 R1343 R1360
66. Dallas N. A., Samuel S., Xia L., Endoglin (CD105): a marker of tumor vasculature and potential target for therapy Clinical Cancer Research 2008 14 7 1931 1937 (Pubitemid 351551101)
67. Santibanez J. F., Letamendia A., Perez-Barriocanal F., Silvestri C., Saura M., Vary C. P., Lopez-Novoa J. M., Attisano L., Bernabeu C., Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signalling Journal of Cell Physiology 2007 210 2 456 468 (Pubitemid 44956891)
68. Pimanda J. E., Chan W. Y., Donaldson I. J., Bowen M., Green A. R., Gottgens B., Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer Blood 2006 107 12 4737 4745 (Pubitemid 43882624)
69. Isenberg J. S., Martin-Manso G., Maxhimer J. B., Roberts D. D., Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies Nature Review Cancer 2009 9 3 182 194
70. Mller T., Renger K., Kuhn W., Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration Archives of Neurology 2004 61 5 657 660 (Pubitemid 38637680)
71. Murphy K. M., Nelson C. A., Sedy J. R., Balancing co-stimulation and inhibition with BTLA and HVEM Nature Review Immunology 2006 6 9 671 681 (Pubitemid 44298216)
72. Cheung T. C., Steinberg M. W., Oborne L. M., Unconventional ligand activation of herpesvirus entry mediator signals cell survival Proceedings of the National Academy of Sciences of the United States of America 2009 106 15 6244 6249
73. Sandberg W. J., Halvorsen B., Yndestad A., Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis Circulation Research 2009 104 1 60 68
74. Gavalda N., Gutierrez H., Davies A. M., Developmental regulation of sensory neurite growth by the tumor necrosis factor superfamily member LIGHT Journal of Neuroscience 2009 29 6 1599 1607
75. Yuzaki M., Cbln and C1q family proteins: new transneuronal cytokines Cell of Molecular and Life Science 2008 65 11 1698 1705
76. Iijima T., Emi K., Yuzaki M., Activity-dependent repression of Cbln1 expression: mechanism for developmental and homeostatic regulation of synapses in the cerebellum Journal of Neuroscience 2009 29 17 5425 5434